Boston Scientific 11K - 2012



UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
 
 
 
 
 
 
 
 
 
 
FORM 11-K
 
FOR ANNUAL REPORTS OF EMPLOYEE STOCK PURCHASE,
SAVINGS AND SIMILAR PLANS PURSUANT TO
SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(Mark One):
 
 
 
 
 
þ
ANNUAL REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
 
For the fiscal year ended December 31, 2012
 
OR
o
TRANSITION REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
 
For the transition period from                 to                             
            
   Commission file number: 1-11083
 
 
 
 
 
 
 
 
 
 A.
Full title of the plan and the address of the plan, if different from that of the issuer named below:
 
 
 
Boston Scientific Corporation
 
 
 
 
401(k) Retirement Savings Plan
 
 
 
 
 
 
 
 
 B.
Name of issuer of the securities held pursuant to the plan and the address of its principal executive
 
 
office:
 
 
 
 
 
 
Boston Scientific Corporation
 
 
 
 
One Boston Scientific Place
 
 
 
 
Natick, MA 01760-1537
 
















Audited Financial Statements
and Supplemental Schedules
 
Boston Scientific Corporation
401(k) Retirement Savings Plan
 
 
As of December 31, 2012 and 2011 and for the Year ended December 31, 2012





















                    

Boston Scientific Corporation 401(k) Retirement Savings Plan
 
Audited Financial Statements
and Supplemental Schedules
 
As of December 31, 2012 and 2011 and for the Year ended December 31, 2012
 
 
Contents
 
 
 
 
 
Report of Independent Registered Public Accounting Firm
1
 
 
 
Audited Financial Statements
 
 
 
Statements of Net Assets Available for Benefits    
2
 
Statement of Changes in Net Assets Available for Benefits
3
 
Notes to the Financial Statements
4-12
 
 
 
Supplemental Schedules
 
 
 
Schedule H, Line 4a - Schedule of Delinquent Participant Contributions
14
 
Schedule H, Line 4i - Schedule of Assets (Held at End of Year)
15
 
 
 
Signature and Exhibits
16-18
 







Report of Independent Registered Public Accounting Firm
The Employee Benefits Committee and Participants
Boston Scientific Corporation 401(k) Retirement Savings Plan

We have audited the accompanying statements of net assets available for benefits of Boston Scientific Corporation 401(k) Retirement Savings Plan as of December 31, 2012 and 2011, and the related statement of changes in net assets available for benefits for the year ended December 31, 2012. These financial statements are the responsibility of the Plan's management. Our responsibility is to express an opinion on these financial statements based on our audits.
We conducted our audits in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. We were not engaged to perform an audit of the Plan's internal control over financial reporting. Our audits included consideration of internal control over financial reporting as a basis for designing audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Plan's internal control over financial reporting. Accordingly, we express no such opinion. An audit also includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements, assessing the accounting principles used and significant estimates made by management, and evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis for our opinion.
In our opinion, the financial statements referred to above present fairly, in all material respects, the net assets available for benefits of Boston Scientific Corporation 401(k) Retirement Savings Plan at December 31, 2012 and 2011, and the changes in its net assets available for benefits for the year ended December 31, 2012, in conformity with U.S. generally accepted accounting principles.
Our audits were conducted for the purpose of forming an opinion on the financial statements taken as a whole. The accompanying supplemental schedules of delinquent participant contributions for the year ended December 31, 2012, and assets (held at end of year) as of December 31, 2012 are presented for purposes of additional analysis and are not a required part of the financial statements but are supplementary information required by the Department of Labor's Rules and Regulations for Reporting and Disclosure under the Employee Retirement Income Security Act of 1974. Such information has been subjected to the auditing procedures applied in our audits of the financial statements and, in our opinion, is fairly stated in all material respects in relation to the financial statements taken as a whole.


/s/ Ernst & Young LLP
Boston, Massachusetts
June 27, 2013








1


Boston Scientific Corporation 401(k) Retirement Savings Plan

Statements of Net Assets Available for Benefits


 
December 31,
 
2012
 
2011
Assets
 
 
 
Investments (at fair value)
$
1,838,739,402

 
$
1,629,592,825

Receivables:
 
 
 
      Participant contributions
23,835

 
—

      Employer contributions
18,914

 
—

      Notes receivable from participants
24,684,530

 
24,865,913

Total receivables
24,727,279

 
24,865,913

 
 
 
 
Net assets
 
 

 reflecting investments at fair value
1,863,466,681

 
1,654,458,738

 
 
 
 
Adjustment from fair value to contract value for
 
 
 
      fully benefit-responsive investment contracts
(13,589,065
)
 
(12,478,331
)
 
 
 
 
Net assets available for benefits
$
1,849,877,616

 
$
1,641,980,407


    

See accompanying notes to the Financial Statements



























2


Boston Scientific Corporation 401(k) Retirement Savings Plan

Statement of Changes in Net Assets Available for Benefits

Year Ended December 31, 2012


Additions:
 
   Investment income:
 
      Dividends
$
45,247,631

      Interest
6,310,641

      Net appreciation in fair value of investments
153,653,762

 
205,212,034

 
 
Interest income on notes receivable from participants
1,032,007

 
 
   Contributions:
 
      Participants
90,992,881

      Employer
63,774,054

      Participant rollovers
5,587,109

 
160,354,044

 
 
Asset transfers in
3,592,760

 
 
Total additions
370,190,845

 
 
Deductions:
 
      Benefits payments
162,216,940

      Administrative expenses
76,696

Total deductions
162,293,636

 
 
Net increase
207,897,209

 
 
Net assets available for benefits:
 
      Beginning of year
1,641,980,407

      End of year
$
1,849,877,616

    


See accompanying notes to the Financial Statements










3
Boston Scientific Corporation 401(k) Retirement Savings Plan

Notes to the Financial Statements

December 31, 2012

    
1. DESCRIPTION OF THE PLAN

The following description of the Boston Scientific Corporation (the Company or Boston Scientific) 401(k) Retirement Savings Plan, as amended (the Plan), provides only general information. Participants should refer to the Summary Plan Description and the Plan document for a more complete description of the Plan's provisions. Copies of these documents are available from the Employee Benefits Committee (the Committee). Capitalized terms used in this description not otherwise defined herein shall each have the meanings set forth in the Plan.

General
The Plan is a defined contribution plan covering all Eligible Employees who have completed thirty days of service and have attained eighteen years of age. If, as a result of temporary or short-term employment at Boston Scientific, an employee satisfies the minimum service requirement for the Plan, he or she will be considered an Eligible Employee for purposes of the Plan. The Plan is subject to the provisions of the Employee Retirement Income Security Act of 1974 (ERISA).

The Plan is administered by the Committee, whose members are appointed by the Chief Executive Officer of the Company. Vanguard Fiduciary Trust Company (Vanguard) is a fiduciary and trustee of the Plan and also serves as the record keeper of each Plan Participant's account.

Contributions
The Plan satisfies the requirements to be a safe harbor plan, in accordance with Internal Revenue Code (IRC) section 401(k)(12)(B). An Eligible Employee may contribute between 1% and 25% of his or her Eligible Compensation to the Plan as Elective Deferrals, up to established federal limits indexed annually. Elective Deferrals include pre-tax contributions and Roth (after-tax) contributions. If elected, Roth contributions are combined with all annual pre-tax contributions in determining the maximum amount which a Participant may contribute in Elective Deferrals each year. Participants are not permitted to make contributions on a traditional after-tax basis.

The Plan provides for “Automatic Enrollments,” whereby an Eligible Employee who completes an Hour of Service with the Company and who would otherwise have been eligible to make Elective Deferrals but did not, is enrolled in the Plan sixty (60) days after he or she satisfies the Plan's eligibility requirements. This feature automatically enrolls each Participant into the Plan at a default rate of 2% of his or her Eligible Compensation on a pre-tax basis for the first plan year. Contributions are allocated to the Qualified Default Investment Alternative (QDIA). Following the first plan year, the rate of contribution of an Eligible Employee's Compensation under the automatic enrollment increases annually in 1% increments, up to a maximum of 6% in the fifth plan year in which the Automatic Compensation Reduction Authorization is in effect. Participants receive advance notice of their right to elect out of both of these automatic Plan features and are permitted to stop or change either feature at any time.



4
Boston Scientific Corporation 401(k) Retirement Savings Plan

Notes to the Financial Statements (continued)


1. DESCRIPTION OF THE PLAN (CONTINUED)

Contributions (Continued)
Vanguard Target Retirement Funds represent the QDIA for the Plan. In the event contributions are made on behalf of a Participant for whom there are no fund allocations elected, the contributions and any associated matching contribution will be allocated to the applicable Target Retirement Fund that is closest to the date the Participant attains age 65.

The Company matches Elective Deferrals at a rate of 200% for the first 2% of the Participant's Eligible Compensation during the Plan year and 50% of the Elective Deferrals thereafter up to a maximum of 6% of the Participant's Eligible Compensation. The Company has the right under the Plan to discontinue or modify its matching contributions at any time. In addition, the Company's Board of Directors may approve additional discretionary contributions to the Plan. No additional discretionary contributions were made during 2012.

The Plan includes a Boston Scientific Common Stock Fund feature. The Plan also includes a Pfizer Common Stock Fund, which was transferred from the Pfizer Savings and Investment Plan on behalf of former employees of Schneider (USA) Inc. following the Company's acquisition of Schneider in September 1998. No additional contributions can be made to the Pfizer Common Stock Fund, and earnings within this fund are allocated in accordance with the Participant's current investment elections under the Plan. A Participant can transfer amounts out of the Pfizer Common Stock Fund to other investment funds within the Plan, and any amount so transferred may not be reallocated to the Pfizer Common Stock Fund.

Participant Accounts and Vesting
A Participant can allocate his or her account among various investment funds. Each Participant's account is credited with the Participant's contribution, the Company's contribution, and an allocation of the earnings and losses for the Participant's particular investment funds. Under current Plan rules, each Participant is fully vested immediately in his or her contributions and Company contributions.

Notes Receivable from Participants
Subject to certain limitations, a Participant may borrow from his or her account a minimum of $1,000 and up to a maximum equal to the lesser of $50,000 or 50 percent of his or her vested account balance. Loan terms range from one to five years in most instances, or up to ten years if the loan is for the purchase of a primary residence. However, Participants of the defined contribution plans of acquired companies may retain the loan terms granted under their former plans. Loans are secured by the balance in the Participant's account and bear an interest rate of the Prime Rate plus 1%. The interest rate is updated monthly, and is applied as of the first day of the month in which the loan is confirmed. Principal and interest are repaid ratably through automatic payroll deductions.










5
Boston Scientific Corporation 401(k) Retirement Savings Plan

Notes to the Financial Statements (continued)


1. DESCRIPTION OF THE PLAN (CONTINUED)

Payment of Benefits
All benefit payments, including balances in the common stock funds, are made in the form of a lump-sum distribution equal to the value of the Participant's account, whether as cash distributions or rollovers. Boston Scientific and Pfizer common stock may be distributed in-kind, if requested by the Participant. If a terminated Participant's account is valued at, and remains in excess of, $5,000 (less any rollover amounts), the Participant has the option of leaving the funds invested in the Plan until attaining the age of 62. While employed by the Company, a Participant may withdraw all or a portion of his or her elective contributions to the extent necessary to meet a Financial Hardship, as provided for in the Plan, not to exceed one Financial Hardship withdrawal per year. Financial Hardship withdrawals are strictly regulated by the Internal Revenue Service (IRS) and a Participant must exhaust all available loan options and available distributions prior to requesting a Financial Hardship withdrawal.

Participants may make withdrawals for any reason after attaining age 59½. Disabled Participants, as defined in the Company's group long-term disability contract, are allowed to make withdrawals at any time regardless of age. The Plan also allows withdrawals regardless of age from a Participant's after-tax accounts for any reason.

Forfeitures
As of December 31, 2012 and 2011, unallocated forfeited non-vested accounts totaled $409,157 and $355,407, respectively. These amounts are used to (a) restore any amount previously forfeited as required by applicable regulations; (b) pay reasonable expenses of administering the Plan; and (c) reduce future employer matching contributions. In 2012, employer contributions were reduced by forfeited non-vested accounts in the amount of $110,892.

Administrative Expenses
The Plan's administrative expenses are paid by the Plan or the Company, in accordance with the Plan's provisions. Administrative expenses paid by the Plan include record keeping and trustee fees. Expenses relating to purchases, sales, or transfers of the Plan's investments are charged to the particular investment fund to which the expenses relate. All other administrative expenses of the Plan are paid by the Company.

Plan Termination
Although it has not expressed any intent to do so, the Company has the right under the Plan to discontinue its contributions at any time and to terminate the Plan subject to the provisions of ERISA. In the event of a termination of the Plan, the assets shall be liquidated and distributed in accordance with the provisions of the Plan and as prescribed by ERISA and the regulations pursuant thereto. Upon termination of the Plan, the Participants will become fully vested in any non-vested portion of their accounts.









6
Boston Scientific Corporation 401(k) Retirement Savings Plan

Notes to the Financial Statements (continued)


2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of Accounting
The accounting records of the Plan are maintained on the accrual basis of accounting in accordance with accounting principles generally accepted in the United States (U.S. GAAP).

Payment of Benefits
Benefits are recorded when paid.

Notes Receivable from Participants
Notes receivable from Participants represent Participant loans that are recorded at their unpaid principal balance plus any accrued but unpaid interest. Interest income on notes receivable from Participants is recorded when it is earned. Related fees are recorded as administrative expenses and are expensed when they are incurred. No allowance for credit losses has been recorded as of December 31, 2012 or 2011. If a Participant ceases to make loan repayments and the plan administrator deems the Participant loan to be a distribution, the Participant loan balance is reduced and a benefit payment is recorded.

Investment Valuation and Income Recognition
The Plan's investments are stated at fair value. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market Participants at the measurement date (an exit price). See Note 4 for further discussion of fair value measurements. The Employee Benefits Committee (the Committee) is responsible for determining the Plan's valuation policies and analyzing information provided by the investment custodians and issuers that is used to determine the fair value of the Plan's investments. The Committee is comprised of members appointed by the Chief Executive Officer and reports to the Audit Committee of the Company.

The Vanguard Retirement Savings Trust III (comprising the Stable Value Fund) is a tax-exempt collective trust that invests in fully benefit-responsive investment contracts issued by insurance companies and commercial banks, and similar types of fixed principal investments. This fund is recorded at fair value (see Note 4); however, since these contracts are fully benefit-responsive, an adjustment is reflected in the statements of net assets available for benefits to present the Stable Value Fund's investment in these investments at contract value. Contract value is the relevant measurement attributable to fully benefit-responsive investment contracts because contract value is the amount Participants would receive if they were to initiate permitted transactions under the terms of the Plan. The contract value represents contributions plus earnings, less Participant withdrawals and administrative expenses.

Purchases and sales of securities are recorded on a trade-date basis. Interest income is accrued when earned. Net appreciation includes the Plan's gains and losses on investments bought and sold, as well as held, during the year. Dividend income is recorded on the ex-dividend date. Capital gain distributions are included in dividend income.




7
Boston Scientific Corporation 401(k) Retirement Savings Plan

Notes to the Financial Statements (continued)


2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

New Accounting Pronouncements
In May 2011, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update 2011-04, Amendments to Achieve Common Fair Value Measurements and Disclosure Requirements in U.S. GAAP and IFRSs, (ASU 2011-04). ASU 2011-04 amended Accounting Standards Codification (ASC) 820, Fair Value Measurement, to converge the fair value measurement guidance in US generally accepted accounting principles and International Financial Reporting Standards (IFRSs). Some of the amendments clarify the application of existing fair value measurement requirements, while other amendments change certain principles or requirements in ASC 820. In addition, ASU 2011-04 requires additional fair value disclosures, although certain of these new disclosures are not required for nonpublic entities, as defined in ASC 820. The amendments are to be applied prospectively and are effective for annual periods beginning after December 15, 2011. Adoption of ASU 2011-04 did not have an effect on the Plan's net assets available for benefits or its changes in net assets available for benefits.

Use of Estimates
The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of additions and deductions during the reporting period. Actual results could differ from those estimates.


3. INVESTMENTS

The following investments represent five percent or more of the Plan's net assets available for benefits.                                        
 
December 31,
 
2012
 
2011
Common Stock:
 
 
 
    Boston Scientific Corporation Common Stock Fund
$
99,551,786

 
$
101,011,309

Mutual Funds:
 
 
 
    Vanguard 500 Index Fund Signal Shares
242,173,637

 
212,778,043

    Vanguard International Growth Fund
181,365,811

 
159,366,747

    Vanguard Growth Index Fund Signal Shares
177,206,599

 
155,584,554

    T. Rowe Price Small-Cap Stock Fund
139,120,276

 
122,964,038

    Vanguard Wellington Fund Investor Shares
136,190,267

 
121,351,973

    Vanguard Total Bond Market Index Fund
125,125,558

 
114,792,522

    Vanguard Windsor II Fund Investor Shares
120,771,598

 
106,071,993

    Vanguard Mid-Cap Growth Fund
95,048,417

 
83,498,406

Stable Value Fund:

 
 
    Vanguard Retirement Savings Trust III (fair value) *
$
269,932,458

 
$
269,473,267

        
* The contract value of the Plan's investment in the Vanguard Retirement Savings Trust III was $256,343,393 and $256,994,936 at December 31, 2012 and 2011, respectively.

8
Boston Scientific Corporation 401(k) Retirement Savings Plan

Notes to the Financial Statements (continued)


3. INVESTMENTS (CONTINUED)

During 2012, the Plan's investments (including gains and losses on investments bought and sold, as well as held during the year) appreciated in value by $153,653,762 as follows:
Mutual funds
$
145,698,436

Common stock
7,955,326

Net appreciation in fair value of investments
$
153,653,762



4. FAIR VALUE MEASUREMENTS

Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date (i.e., an exit price). ASC 820 establishes a three-level valuation hierarchy for disclosure of fair value measurements. The categorization of financial assets and financial liabilities within the valuation hierarchy is based upon the lowest level of input that is significant to the measurement of fair value. The three levels of the hierarchy are defined as follows:

Level 1 - Inputs to the valuation methodology are quoted market prices for identical assets or liabilities.

Level 2 - Inputs to the valuation methodology are other observable inputs, including quoted market prices for similar assets or liabilities and market-corroborated inputs.

Level 3 - Inputs to the valuation methodology are unobservable inputs based on management's best estimate of inputs market participants would use in pricing the asset or liability at the measurement date, including assumptions about risk.

The following is a description of the valuation methodologies used for assets measured at fair value. The Plan's valuation methodology used to measure the fair value of common stock and mutual funds was derived from quoted market prices, as substantially all of these instruments have active markets. The investment in the Stable Value Fund is stated at fair value based on the year end market value of each unit held, which is derived from the market value of the underlying net assets disclosed in the audited financial statements of the Vanguard Retirement Savings Trust III.













9
Boston Scientific Corporation 401(k) Retirement Savings Plan

Notes to the Financial Statements (continued)


4. FAIR VALUE MEASUREMENTS (CONTINUED)

The following tables set forth by level, within the fair value hierarchy, the Plan's investments carried at fair value as of December 31, 2012 and 2011.

 
Investments at Fair Value as of December 31, 2012
 
Level 1
Level 2
Level 3
Total
Mutual funds:
 
 
 
 
     Index
$
544,505,794

$
—

$
—

$
544,505,794

     Growth
613,162,911

—

—

613,162,911

     Other
171,995,834

—

—

171,995,834

     Balanced
136,190,267

—

—

136,190,267

Common stock
102,952,138

—

—

102,952,138

Stable value fund †
—

269,932,458

—

269,932,458

Total investments at fair value
$
1,568,806,944

$
269,932,458

$
—

$
1,838,739,402


 
Investments at Fair Value as of December 31, 2011
 
Level 1
Level 2
Level 3
Total
Mutual funds:
 
 
 
 
     Index
$
483,155,119

$
—

$
—

$
483,155,119

     Growth
504,814,075

—

—

504,814,075

     Other
146,676,955

—

—

146,676,955

     Balanced
121,351,973

—

—

121,351,973

Common stock
104,121,436

—

—

104,121,436

Stable value fund †
—

269,473,267

—

269,473,267

Total investments at fair value
$
1,360,119,558

$
269,473,267

$
—

$
1,629,592,825

† This category includes a common/collective trust fund that is designed to deliver safety and stability by preserving principal and accumulating earnings. This fund is primarily invested in guaranteed investment contracts and synthetic investment contracts. Participant-directed redemptions have no restrictions; however, the Plan is required to provide a one year redemption notice to liquidate its entire share in the fund. The fair value of this fund has been estimated based on the fair value of the underlying investment contracts in the fund as reported by the issuer of the fund. The fair value differs from the contract value. As previously discussed in Note 2, contract value is the relevant measurement attributable to fully benefit-responsive investment contracts because contract value is the amount Participants would receive if they were to initiate permitted transactions under the terms of the Plan.






10
Boston Scientific Corporation 401(k) Retirement Savings Plan

Notes to the Financial Statements (continued)


5. TRANSACTIONS WITH PARTIES-IN-INTEREST

The Plan invests in certain funds managed by an affiliate of Vanguard. As noted in Note 1, Vanguard is a fiduciary and trustee of the Plan and also serves as the record keeper to maintain the individual accounts of each Participant. The Plan also invests in the common stock of the Company. Transactions in these investments qualify as party-in-interest transactions; however, they are exempt from the prohibited transaction rules under ERISA. Fees for legal, accounting, and other services rendered during the year by parties-in-interest were paid by the Company.


6. RISKS AND UNCERTAINTIES

The Plan invests in various investment securities. Investment securities are exposed to various risks such as overall market volatility, interest rate, and credit risks. Due to the level of risk associated with certain investment securities, it is at least reasonably possible that changes in the values of investment securities will occur in the near term and that such changes could materially affect Participants' account balances and the amounts reported in the statements of net assets available for benefits. During 2012, net appreciation in fair value of investments totaled $153,653,762.



7. INCOME TAX STATUS

The Plan has received a determination letter from the IRS dated March 4, 2002, stating that the Plan is qualified under Section 401(a) of the IRC and, therefore, the related trust is exempt from taxation. Once qualified, the Plan is required to operate in conformity with the IRC to maintain its qualified status. Subsequent to this determination by the IRS, the Plan was amended. The Company is committed to ensuring that the Plan is compliant with the IRC, and has indicated that it will take the necessary steps, if any, to bring the Plan's operations into compliance with the IRC. The Plan was amended and restated as of January 1, 2011 and an application for a new determination letter was submitted and is pending IRS action.

U.S. GAAP requires plan management to evaluate uncertain tax positions taken by the Plan. The financial statement effects of a tax position are recognized when the position is more likely than not, based on the technical merits, to be sustained upon examination by the IRS. The plan administrator has analyzed the tax positions taken by the Plan, and has concluded that as of December 31, 2012 and 2011, there were no uncertain positions taken or expected to be taken. The Plan has recognized no interest or penalties related to uncertain tax positions. The Plan is subject to routine audits by taxing jurisdictions; however, there are currently no audits for any tax periods in progress. The Plan administrator believes it is no longer subject to income tax examination for plan years prior to 2009.








11
Boston Scientific Corporation 401(k) Retirement Savings Plan

Notes to the Financial Statements (continued)


8. RECONCILIATION OF FINANCIAL STATEMENTS TO FORM 5500

The following is a reconciliation of the net assets available for benefits per the financial statements to the Form 5500 as of December 31, 2012 and 2011:
 
December 31,
 
2012
 
2011
Net assets available for benefits per the financial statements
$
1,849,877,616

 
$
1,641,980,407

Adjustments from contract value to fair value for fully benefit-responsive
 
 
 
          investment contracts
13,589,065

 
12,478,331

Deemed distributions
(94,916
)
 
(82,338
)
Net assets available for benefits per the Form 5500
$
1,863,371,765

 
$
1,654,376,400


The following is a reconciliation of the net increase in the statement of changes in net assets available for benefits per the financial statements to net income per the Form 5500 as of December 31, 2012:
 
December 31,
 
2012
Net increase per the financial statements
$
207,897,209

Adjustment from fair value to contract value for fully benefit-responsive
 
 investment contracts
1,110,734

Deemed distributions
(12,578
)
Transfers in
(3,592,760
)
Net income per the Form 5500
$
205,402,605



9. DELINQUENT PARTICIPANT CONTRIBUTIONS

In connection with a Department of Labor (DOL) examination that concluded in 2011, to fully correct identified errors and successfully conclude the examination, the Company remitted a total of $25,426 to the Plan as lost earnings on Participant contributions that were paid to the Plan during the plan years 2007 through 2011 but were deemed by the DOL to have been delinquent.  The Company is in the process of filing Forms 5330 to pay the related excise taxes.









12



















SUPPLEMENTAL SCHEDULES

































Boston Scientific Corporation 401(k) Retirement Savings Plan
EIN #04-2695240
Plan #001

Schedule H, Line 4a - Schedule of Delinquent Participant Contributions

Year Ended December 31, 2012

 
Participant Contributions Transferred Late to Plan
Total that Constitute Nonexempt Prohibited Transactions
Total Fully Corrected Under VFCP and PTE
2002-51
Year
Check here
if Late Participant Loan Repayments are included: S

Contributions Not Corrected
Contributions Corrected Outside
VFCP
Contributions Pending
Correction in
VFCP
2011
24,909,176

—

24,909,176 (1)
—

—

2010
26,137,082

—

26,137,082 (1)
—

—

2009
9,473,879

—

9,473,879 (1)
—

—

2008
15,701,358

—

15,701,358 (1)
—

—

2007
10,441,235

—

10,441,235 (1)
—

—


(1) 
Represents Participant contributions and loan repayments deemed delinquent by the DOL in connection with its examination that concluded in 2011. To fully correct identified errors and conclude the examination, the Company remitted lost earnings in the total amount of $25,426 on Participant contributions that were paid to the Plan during plan years 2007 through 2011.  The Company is in the process of filing Forms 5330 to pay the related excise taxes.





















14


Boston Scientific Corporation 401(k) Retirement Savings Plan
EIN #04-2695240
Plan #001

Schedule H, Line 4i - Schedule of Assets (Held at End of Year)

December 31, 2012
                    

Identity of Issue
Shares or Units

 
Current Value

*Vanguard Group
 
 
 
     500 Index Fund Signal Shares
2,231,604

 
$
242,173,637

     International Growth Fund
9,411,822

 
181,365,811

     Growth Index Fund Signal Shares
5,222,711

 
177,206,599

     Wellington Fund Investor Shares
4,024,535

 
136,190,267

     Total Bond Market Index Fund
11,282,737

 
125,125,558

     Windsor II Fund Investor Shares
4,110,674

 
120,771,598

     Mid-Cap Growth Fund
4,666,098

 
95,048,417

     Target Retirement 2035
2,448,174

 
34,494,770

     Target Retirement 2030
1,302,857

 
30,460,792

     Target Retirement 2040
1,225,618

 
28,409,816

     Target Retirement 2025
2,041,320

 
27,741,537

     Target Retirement 2020
1,021,918

 
24,352,316

     Target Retirement 2045
1,633,370

 
23,765,537

     Target Retirement 2015
1,207,917

 
16,161,934

     Target Retirement Income
1,164,559

 
14,195,973

     Target Retirement 2050
581,082

 
13,417,192

     Target Retirement 2010
104,337

 
2,517,651

     Target Retirement 2055
59,169

 
1,467,398

     Target Retirement 2060
3,852

 
84,006

  T. Rowe Price Small-Cap Stock Fund
4,088,166

 
139,120,276

  Harbor International Fund Institutional
257,062

 
15,968,688

  Artisan Mid Cap Value Fund Investor Shares
760,704

 
15,815,033

*Stable Value Fund
 
 
 
     Vanguard Retirement Savings Trust III
256,343,393

 
269,932,458

*Boston Scientific Corporation Common Stock Fund
17,373,785

 
99,551,786

  Pfizer Common Stock Fund
135,580

 
3,400,352

*Participants' notes receivable, interest rates 4.25% - 9.25%
 
 
24,684,530

 
 
 
$
1,863,423,932



* Indicates party-in-interest to the Plan.

Note: Cost information is not presented because all investments are Participant-directed.




15



SIGNATURES



Pursuant to the requirements of the Securities Exchange Act of 1934, the trustee (or other persons who administer the employee benefit plan) has duly caused this annual report to be signed on its behalf by the undersigned hereunto duly authorized.


 
 
 
 
 
Boston Scientific Corporation
 
 
 
 
 
401(k) Retirement Savings Plan
 
 
 
 
 
 
 
 
 
 
 
 
Date:
June 27, 2013
 
 
 
By:
/s/ David A. Appugliese, J.D.
 
 
 
 
 
 
David A. Appugliese, J.D.
 
 
 
 
 
 
Chair, Employee Benefits Committee
 
 
 
 
 
 
 






































16


EXHIBIT INDEX



Exhibit Number
Description
 
 
 
 
 
 
 
 
23
Consent of Independent Registered Public Accounting Firm



















































17